Alpha 2.0
Login Register
» Authors » Simona Rizzato

Simona Rizzato

Explore the profile of Simona Rizzato including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 19
Citations 387
Followers 0
Related Specialties
Oncology
Neurology
Pulmonary Medicine
Top 10 Co-Authors
Giuseppe Lombardi
Roberta Ruda
Vittorina Zagonel
Gianpiero Fasola
Marica Eoli
Mario Caccese
Francesco Pasqualetti
Francesco Cortiula
Gian Luca De Salvo
Fabio Puglisi
Published In
Lung Cancer
J Thorac Oncol
Cancers (Basel)
J Neurooncol
Curr Treat Options Neurol
Affiliations
Soon will be listed here.
Recent Articles
1.
Oligometastatic NSCLC: Current Perspectives and Future Challenges
Torresan S, Costa J, Zanchetta C, De Marchi L, Rizzato S, Cortiula F
Curr Oncol . 2025 Feb; 32(2). PMID: 39996875
Oligometastatic non-small cell lung cancer (NSCLC) represents a separate entity with a different biology and prognosis compared to stage IV NSCLC. Challenges range from the very definition of oligometastatic disease...
2.
The Role of ctDNA in the Management of Non-Small-Cell Lung Cancer in the AI and NGS Era
Costa J, Membrino A, Zanchetta C, Rizzato S, Cortiula F, Rossetto C, et al.
Int J Mol Sci . 2025 Jan; 25(24. PMID: 39769431
Liquid biopsy (LB) involves the analysis of circulating tumour-derived DNA (ctDNA), providing a minimally invasive method for gathering both quantitative and qualitative information. Genomic analysis of ctDNA through next-generation sequencing...
3.
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial
Piccirillo M, Bonanno L, Garassino M, Esposito G, Dazzi C, Cavanna L, et al.
J Thorac Oncol . 2022 Jun; 17(9):1086-1097. PMID: 35659580
Introduction: Adding bevacizumab to erlotinib prolonged progression-free survival (PFS) of patients with EGFR-mutated advanced NSCLC in the Japanese JO25567 trial, but limited data were available in non-Asian patients. BEVERLY is...
4.
Definition of the Prognostic Role of MGMT Promoter Methylation Value by Pyrosequencing in Newly Diagnosed IDH Wild-Type Glioblastoma Patients Treated with Radiochemotherapy: A Large Multicenter Study
Caccese M, Simonelli M, Villani V, Rizzato S, Ius T, Pasqualetti F, et al.
Cancers (Basel) . 2022 May; 14(10). PMID: 35626029
Background. O6-methylguanine (O6-MeG)-DNA methyltransferase (MGMT) methylation status is a predictive factor for alkylating treatment efficacy in glioblastoma patients, but its prognostic role is still unclear. We performed a large, multicenter...
5.
Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial)
Lombardi G, Del Bianco P, Brandes A, Eoli M, Ruda R, Ibrahim T, et al.
Eur J Cancer . 2021 Aug; 155:179-190. PMID: 34388515
Background: The REGOMA trial showed that regorafenib significantly improved overall survival in patients with recurrent glioblastoma compared with lomustine. Patients treated with regorafenib experienced a higher occurrence of grade 3-4...
6.
Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO)
Padovan M, Eoli M, Pellerino A, Rizzato S, Caserta C, Simonelli M, et al.
Cancers (Basel) . 2021 Jul; 13(11). PMID: 34204877
Background: Depatuxizumab Mafodotin (Depatux-M; ABT-414) is an antibody-drug conjugate consisting of a specific antibody against activated EGFR and a cytotoxic agent with antimicrotubule activity. The INTELLANCE 2/EORTC 1410 phase 2...
7.
Adjuvant chemotherapy after severe myelotoxicity during chemoradiation phase in malignant gliomas. Is it feasibile? Results from AINO study (Italian Association for Neuro-Oncology)
Villani V, Anghileri E, Prosperini L, Lombardi G, Ruda R, Gaviani P, et al.
J Neurol . 2021 Feb; 268(8):2866-2875. PMID: 33609154
Background: Malignant gliomas (MG) are aggressive brain tumours in adults. The standard of care is concurrent radiation plus temozolomide (TMZ) [chemo-radiotherapy (CRT)] followed by TMZ maintenance up to 6 months....
8.
Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study
de Marinis F, Laktionov K, Poltoratskiy A, Egorova I, Hochmair M, Passaro A, et al.
Lung Cancer . 2021 Jan; 152:127-134. PMID: 33387727
Objectives: Randomized controlled trials have demonstrated that afatinib is a suitable treatment option for patients with epidermal growth factor receptor mutation-positive (EGFRm +) non-small cell lung cancer (NSCLC). However, such...
9.
Platinum-Based Chemotherapy in Older Patients with Non-Small Cell Lung Cancer: What to Expect in the Real World
Pelizzari G, Cortiula F, Giavarra M, Bartoletti M, Lisanti C, Buoro V, et al.
Drugs Aging . 2020 Jul; 37(9):677-689. PMID: 32681401
Background: The role of platinum-based chemotherapy (PBC) for the treatment of older patients with non-small cell lung cancer (NSCLC) is still a matter of debate, despite the advent of immunotherapy....
10.
A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib
Santangelo A, Rossato M, Lombardi G, Benfatto S, Lavezzari D, De Salvo G, et al.
Neuro Oncol . 2020 Jul; 23(2):264-276. PMID: 32661549
Background: Patients with glioblastoma (GBM) have a dramatically poor prognosis. The recent REGOMA trial suggested an overall survival (OS) benefit of regorafenib in recurrent GBM patients. Considering the extreme genetic...